Literature DB >> 22321462

Theories of the pathogenesis of hepatic encephalopathy.

E Anthony Jones1, Kevin D Mullen.   

Abstract

The earliest hypothesis of the pathogenesis of HE implicated ammonia, although effects of appreciable concentrations of this neurotoxin did not resemble HE. Altered eurotransmission in the brain was suggested by similarities between increased GABA-mediated inhibitory neurotransmission and HE, specifically decreased consciousness and impaired motor function. Evidence of increased GABAergic tone in models of HE has accumulated; potential mechanisms include increased synaptic availability of GABA and accumulation of natural benzodiazepine receptor ligands with agonist properties. Pathophysiological concentrations of ammonia associated with HE, have the potential of enhancing GABAergic tone by mechanisms that involve its interactions with the GABAa receptor complex.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22321462     DOI: 10.1016/j.cld.2011.12.010

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  16 in total

1.  Differences in cognitive function between patients with viral and alcoholic compensated liver cirrhosis.

Authors:  Yunhyeong Lee; Chulho Kim; Ki Tae Suk; Hui Chul Choi; Chang Seok Bang; Jai Hoon Yoon; Gwang Ho Baik; Dong Joon Kim; Min Uk Jang; Jong Hee Sohn
Journal:  Metab Brain Dis       Date:  2015-11-12       Impact factor: 3.584

2.  Minimal hepatic encephalopathy in children with liver cirrhosis: diffusion-weighted MR imaging and proton MR spectroscopy of the brain.

Authors:  Ahmed Abdel Khalek Abdel Razek; Ahmed Abdalla; Amany Ezzat; Ahmed Megahed; Tarek Barakat
Journal:  Neuroradiology       Date:  2014-07-25       Impact factor: 2.804

3.  Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis.

Authors:  Ayse L Mindikoglu; Antone R Opekun; Nagireddy Putluri; Sridevi Devaraj; David Sheikh-Hamad; John M Vierling; John A Goss; Abbas Rana; Gagan K Sood; Prasun K Jalal; Lesley A Inker; Robert P Mohney; Hocine Tighiouart; Robert H Christenson; Thomas C Dowling; Matthew R Weir; Stephen L Seliger; William R Hutson; Charles D Howell; Jean-Pierre Raufman; Laurence S Magder; Cristian Coarfa
Journal:  Transl Res       Date:  2017-12-12       Impact factor: 7.012

4.  Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; Puneeta Tandon; Florence Wong; Patrick S Kamath; Scott W Biggins; Guadalupe Garcia-Tsao; Jennifer Lai; Michael B Fallon; Paul J Thuluvath; Hugo E Vargas; Benedict Maliakkal; Ram M Subramanian; Leroy R Thacker; K Rajender Reddy
Journal:  Aliment Pharmacol Ther       Date:  2019-04-29       Impact factor: 8.171

Review 5.  Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?

Authors:  Lise Lotte Gluud; Gitte Dam; Mette Borre; Iñigo Les; Juan Cordoba; Giulio Marchesini; Niels Kristian Aagaard; Hendrik Vilstrup
Journal:  Metab Brain Dis       Date:  2012-12-29       Impact factor: 3.584

Review 6.  Acetyl-L-carnitine in hepatic encephalopathy.

Authors:  Michele Malaguarnera
Journal:  Metab Brain Dis       Date:  2013-02-08       Impact factor: 3.584

Review 7.  Current pathogenetic aspects of hepatic encephalopathy and noncirrhotic hyperammonemic encephalopathy.

Authors:  Halina Cichoż-Lach; Agata Michalak
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

8.  A New Look at Precipitants of Overt Hepatic Encephalopathy in Cirrhosis.

Authors:  Ganesh Pantham; Anthony Post; Deepak Venkat; Douglas Einstadter; Kevin D Mullen
Journal:  Dig Dis Sci       Date:  2017-05-30       Impact factor: 3.199

9.  Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.

Authors:  Robert S Rahimi; Amit G Singal; Jennifer A Cuthbert; Don C Rockey
Journal:  JAMA Intern Med       Date:  2014-11       Impact factor: 21.873

10.  Lowering blood ammonia prevents hepatocyte injury and apoptosis.

Authors:  Guanmin Gao; Zujiang Yu; Jingya Yan; Jingjing Li; Shen Shen; Bin Jia; Kelei Guan; Xiaojuan Gao; Quancheng Kan
Journal:  Int J Clin Exp Med       Date:  2015-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.